BioN­Tech ex­pands mR­NA man­u­fac­tur­ing to Sin­ga­pore as clam­or for Covid-19 vac­cine and boost­ers swells

In the race to tur­bocharge pro­duc­tion of its Covid-19 vac­cine, BioN­Tech is set­ting down roots in Sin­ga­pore. The site will be home to BioN­Tech’s south­east Asia re­gion­al head­quar­ters, and a key dri­ver in the Ger­man drug­mak­er’s plans post-Covid-19.

The fa­cil­i­ty will be out­fit­ted to pro­duce a wide range of mR­NA vac­cines and ther­a­peu­tics be­yond their Covid-19 col­lab­o­ra­tion with Pfiz­er, from treat­ments for in­fec­tious dis­eases to can­cer. The plant will have fill-fin­ish ca­pa­bil­i­ty and an­nu­al ca­pac­i­ty of some sev­er­al hun­dred mil­lions of dos­es of mR­NA-based vac­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER